Oral mucositis is a mouth sore that typically occur due to the consequences of various cancer therapy such as chemotherapy, radiation, and/or surgery. High doses of chemotherapy and radiation therapy to the head and neck region are the major cause of oral mucositis. Cancer treatment effectively targets the cancer cells but also inadvertently affect healthy normal cells that rapidly develop into oral mucosa lining of the mouth. Amifostine (Ethyol®) is a commonly used drug to protect by damages to the mucosa caused by cancer treatment such as radiation and chemotherapy.
Growing prevalence of cancer cases around the globe is fueling the market growth of oral mucositis drugs. According to WHO, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Moreover, rising approval of Oral Mucositis drugs is another major factor in propelling market growth. For instance, in March 2018, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to GC4419, a highly selective and potent small molecule dismutase mimetic, for the reduction of the duration, incidence, and severity of severe oral mucositis induced by radiation therapy with or without systemic therapy.
According to the Oncology Nursing Society, about 40 percent of patients who are given standard-dose chemotherapy experience oral mucositis, while nearly 100 percent of patients being treated using radiotherapy for head and neck cancers show signs of the complication.
North America is expected to gain significant growth over the forecast period and this can be attributed to the high prevalence of cancer in the region. According to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States. Moreover, increasing spending on cancer treatment in the U.S. government is further expected to foster regional market growth. According to the National Cancer Institute, total expenditures for cancer drugs, including new immunotherapies and targeted agents, in the United States jumped from $26.8 billion in 2011 to $42.1 billion in 2016.
Key Developments:
• In February 2019, Innovation Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that the U.S. Patent & Trademark Office issued a new patent to the Company for the treatment of oral mucositis. The patent (U.S. Patent Number 10206894) covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts.
• In September 2017, Onxeo Partners with Monopar Therapeutics on Development of Severe Oral Mucositis Drug called clonidine mucoadhesive buccal tablet.
World economic growth, the Oral Mucositis Drugs industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Oral Mucositis Drugs market size to maintain the average annual growth rate of 0.0717097253002 from 290.0 million $ in 2014 to 410.0 million $ in 2020, Stratagem Market Insights analysts believe that in the next few years, Oral Mucositis Drugs market size will be further expanded, we expect that by 2026, The market size of the Oral Mucositis Drugs will reach 620.0 million $.
This Report covers the manufacturers' data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the World, which shows a regional development status, including market size, volume, and value, as well as price data.
Besides, the report also covers segment data, including type segment, industry segment, channel segment, etc. cover different segment market sizes, both volume, and value. It also covers different industry's clients information, which is very important for the manufacturers. If you need more information,
Section 1: Definition
Section (2 3): Manufacturer Detail
3M Healthcare
GSK
Pfizer
Colgate-Palmolive
Norgine
Biovitrum
Valeant Pharmaceuticals
EUSA Pharma
Camurus
Mission Pharmacal
Clinigen Group
Midatech Pharma
Alliance Pharma
AMAG Pharmaceuticals
Section 4: Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)
Section (5 6 7):
Product Type Segmentation
-- Mouthwash
-- Pain Control Medication
Industry Segmentation
-- Chemotherapy
-- Radiotherapy
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2020-2026)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
Request Discount 
Inquire Before Buy
